Holen Sie sich die Stockscreener-App
8.10
3.28%
-0.275
Schlusskurs vom Vortag:
$8.375
Offen:
$8.53
24-Stunden-Volumen:
1.16M
Relative Volume:
0.79
Marktkapitalisierung:
$719.32M
Einnahmen:
$73.48M
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-3.60
EPS:
-2.25
Netto-Cashflow:
$-67.17M
1W Leistung:
+3.18%
1M Leistung:
-12.53%
6M Leistung:
+13.13%
1J Leistung:
+44.64%
1-Tages-Spanne:
$8.02
$8.54
1-Wochen-Bereich:
$7.73
$9.74
52-Wochen-Spanne:
$2.8262
$11.40
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Vergleichen Sie PSNL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.10 | 743.74M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
618.86 | 227.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
238.37 | 165.99B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
713.35 | 56.89B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.52 | 41.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
242.41 | 41.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
BTIG Reiterates Buy Rating for Personalis (PSNL) with $12 Target - GuruFocus
Is Personalis Inc. stock attractive for long term wealth building2025 Historical Comparison & Expert Curated Trade Setups - ulpravda.ru
Why Personalis Inc. stock remains a top recommendationJuly 2025 Market Mood & Risk Controlled Stock Alerts - ulpravda.ru
Is Personalis Inc. stock attractive for hedge fundsEarnings Recap Summary & Consistent Return Strategy Ideas - ulpravda.ru
Personalis (PSNL) Achieves Remarkable Growth in Clinical Volumes - GuruFocus
Can Personalis Inc. stock outperform in 2025 bull marketGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Is Personalis Inc. stock a buy for dividend growth2025 Macro Impact & Real-Time Chart Breakout Alerts - ulpravda.ru
Will Personalis Inc. stock remain a Wall Street favoriteQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - ulpravda.ru
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace
PSNL Achieves Key Medicare Coverage Milestone for Breast Cancer - GuruFocus
Personalis reports select preliminary fourth quarter and full year 2025 results - MarketScreener
Institutional Investors Are Personalis, Inc.'s (NASDAQ:PSNL) Biggest Bettors and Were Rewarded After Last Week's US$105m Market Cap Gain - 富途牛牛
Personalis (NASDAQ:PSNL) delivers shareholders splendid 54% CAGR over 3 years, surging 15% in the last week alone - simplywall.st
Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Will Personalis Inc stock remain a Wall Street favoriteJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - moha.gov.vn
Quant Funds Rotate Into Pavna Industries Limited StockTechnical Analysis Insights & Stay Invested. Stay Smart. - earlytimes.in
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) - Insider Monkey
Personalis Outpaces The Market With Cancer Test Breakthroughs - Finimize
Would You Still Hold Personalis Stock If It Fell Another 30%? - Trefis
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Personalis Inc. (04X) stock split increase liquidityRate Cut & Entry and Exit Point Strategies - Улправда
How Personalis Inc. stock reacts to bond yieldsWeekly Trading Summary & Safe Entry Point Alerts - ulpravda.ru
Personalis (NASDAQ:PSNL) Sees Strong Trading VolumeHere's Why - MarketBeat
Nasdaq Moves: How Personalis Inc. stock reacts to bond yieldsWeekly Stock Recap & Reliable Price Action Trade Plans - ulpravda.ru
Aug Opening: How risky is Personalis Inc. stock nowTrade Exit Summary & Daily Price Action Insights - Улправда
Revenue Check: Will Personalis Inc. (04X) stock split increase liquidityJuly 2025 Price Swings & Daily Price Action Insights - Улправда
How risky is Personalis Inc. stock nowJuly 2025 Earnings & Safe Investment Capital Preservation Plans - Улправда
Personalis study shows cancer blood test predicts immunotherapy outcomes By Investing.com - Investing.com Nigeria
Personalis study shows cancer blood test predicts immunotherapy outcomes - Investing.com
Personalis announces new publication applying ultrasensitive ctDNA testing - marketscreener.com
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors - Business Wire
About Us - FinancialContent
Personalis (NASDAQ:PSNL) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer - Business Wire
Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds - Yahoo Finance
Personalis, Inc. $PSNL Shares Purchased by Blue Water Life Science Advisors LP - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 38% But Its P/S Still Looks Reasonable - 富途牛牛
Personalis (NASDAQ:PSNL) Stock Price Down 4.8%What's Next? - MarketBeat
Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen - MarketBeat
Is Personalis Inc. (04X) stock undervalued by metricsEarnings Miss & Short-Term High Return Strategies - Newser
Geode Capital Management LLC Buys 851,422 Shares of Personalis, Inc. $PSNL - MarketBeat
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):